An Examination of a Novel Weight Loss Formula on Anthropometry and Indices of Cardiovascular Disease Risk

Studies from Africa report supplementation with Dichrostachys glomerata (DG; 200–400 mg/d) has led to significant reductions in weight and fat in obese individuals, without exercise or diet intervention. The purpose of this study was to examine if adding DG to weight loss supplements with caffeine [WL+C] containing; DG (300mg), Clubmoss extract (10mg), Caffeine (150mg; XR [77% caffeine] | 250mg; anhydrous [98.5% caffeine]), Sensoril® (125mg), and Capsimax ® (50mg) or without caffeine [WL] containing; DG (300mg), Sensoril® (250mg; Ashwaganda), Bioperine (5mg), Capsimax® (50mg; 4% Capsaicinoids), Rhodiola rosea extract (60mg), L-Theanine (100mg), Clubmoss extract (5mg), and Bacopa monneri extract (50mg), would promote weight loss in overweight persons, without exercise or dietary modification. In a double-blind, parallel, stratified random, placebo-controlled trial, participants (N=68 [M: 31, W: 37], 37±5 yr, 88.9±16.6 kg, BMI: 25-34.9 kg/m2 , Fat: 35.2±7.7%, Activity: 6,857±1,512 steps/wk) ingested a DG containing weight loss supplement for 12 weeks. Measurements were obtained for body weight, body composition, anthropometry, blood chemistries, resting energy expenditure, and hunger and satiety at baseline and after 4, 8, and 12-weeks. Supplementation was shown, using GLM, to have no significant differences between groups for measures of body composition using the current dose. Supplement groups decreased in FM (WL: -0.56±0.95 [-1.02, -0.14]; WL: -0.63±1.47 [-1.23, -0.02] kg) at wk4 and wk8, respectively, and body fat (WL: -0.63±1.26 [-1.16, -0.10]; WL: -0.78±1.31 [-1.45, 0.07] %) at wk8 and wk12, respectively, with indications of having greater effect on males. As well, REE improved (WL+C: 111±220 [10, 207] kcal/d; WL+C: 1.57±2.37 [0.5, 2.6] kcal/kg/d) by wk12. Supplement groups also reported less hunger and more satiety with some sleep quality improvements (diminished sleep quality for WL+C), overall. No significant effects or differences were observed in any other measure. The addition of caffeine did not incur additional benefits. Consequently, further research is required to determine an effective dose and thereafter, paired with a diet and/or exercise program for functional assessment of weight loss potential

Proceedings of the Thirteenth International Society of Sports Nutrition (ISSN) Conference and Expo

Meeting Abstracts: Proceedings of the Thirteenth International Society of Sports Nutrition (ISSN) Conference and Expo Clearwater Beach, FL, USA. 9-11 June 201

An Examination of a Novel Weight Loss Formula on Anthropometry and Indices of Cardiovascular Disease Risk

Studies from Africa report supplementation with Dichrostachys glomerata (DG; 200–400 mg/d) has led to significant reductions in weight and fat in obese individuals, without exercise or diet intervention. The purpose of this study was to examine if adding DG to weight loss supplements with caffeine [WL+C] containing; DG (300mg), Clubmoss extract (10mg), Caffeine (150mg; XR [77% caffeine] | 250mg; anhydrous [98.5% caffeine]), Sensoril® (125mg), and Capsimax ® (50mg) or without caffeine [WL] containing; DG (300mg), Sensoril® (250mg; Ashwaganda), Bioperine (5mg), Capsimax® (50mg; 4% Capsaicinoids), Rhodiola rosea extract (60mg), L-Theanine (100mg), Clubmoss extract (5mg), and Bacopa monneri extract (50mg), would promote weight loss in overweight persons, without exercise or dietary modification. In a double-blind, parallel, stratified random, placebo-controlled trial, participants (N=68 [M: 31, W: 37], 37±5 yr, 88.9±16.6 kg, BMI: 25-34.9 kg/m2 , Fat: 35.2±7.7%, Activity: 6,857±1,512 steps/wk) ingested a DG containing weight loss supplement for 12 weeks. Measurements were obtained for body weight, body composition, anthropometry, blood chemistries, resting energy expenditure, and hunger and satiety at baseline and after 4, 8, and 12-weeks. Supplementation was shown, using GLM, to have no significant differences between groups for measures of body composition using the current dose. Supplement groups decreased in FM (WL: -0.56±0.95 [-1.02, -0.14]; WL: -0.63±1.47 [-1.23, -0.02] kg) at wk4 and wk8, respectively, and body fat (WL: -0.63±1.26 [-1.16, -0.10]; WL: -0.78±1.31 [-1.45, 0.07] %) at wk8 and wk12, respectively, with indications of having greater effect on males. As well, REE improved (WL+C: 111±220 [10, 207] kcal/d; WL+C: 1.57±2.37 [0.5, 2.6] kcal/kg/d) by wk12. Supplement groups also reported less hunger and more satiety with some sleep quality improvements (diminished sleep quality for WL+C), overall. No significant effects or differences were observed in any other measure. The addition of caffeine did not incur additional benefits. Consequently, further research is required to determine an effective dose and thereafter, paired with a diet and/or exercise program for functional assessment of weight loss potential